Energy metabolism in motor neuron diseases

About the project

Work in our lab is aimed at understanding the pathophysiological mechanisms leading to neurodegeneration in two types of motor neuron diseases (MND): the childhood onset spinal muscular atrophy and the adult-onset Amyotrophic Lateral Sclerosis (ALS). We are more specifically investigating whether changes in cellular metabolism could precipitate neuronal death across a wide range of MND models. Ultimately, we hope to identify much-needed novel therapeutic targets for these devastating diseases.


Medical Research Council, Motor Neurone Disease Association


Chaytow H, Carroll E, Gordon D, Huang YT, Van Der Hoorn D, Smith HL, Becker T, Becker CG, Faller KME, Talbot K, Gillingwater TH
Targeting phosphoglycerate kinase 1 with terazosin improves motor neuron phenotypes in multiple models of amyotrophic lateral sclerosis
EBioMed. 2022;83:104202
2022 Aug 10
Chaytow H, Faller KME, Huang YT, Gillingwater TH
Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine.
Cell Rep Med. 2021;2(7)
2021 Jul 20

Primary location


Principal Investigator

Other people involved

Professor Tom Gillingwater (Edinburgh)

Kim Morris (Research Assistant)